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Abstract 
Background: Moringa oleifera Lam., an herb commonly consumed by HIV‑infected people on antiretroviral therapy, 
inhibits cytochrome P450 3A4, 1A2 and 2D6 activity in vitro; and may alter the pharmacokinetics (PK) of antiretroviral 
drugs metabolized via the same pathways. However, in vitro drug interaction activity may not translate to a clinically 
significant effect. Therefore, the effect of moringa leaf powder on the PK of nevirapine in HIV‑infected people was 
investigated.
Methods: Adult patients at steady‑state dosing with nevirapine were admitted for 12‑h intensive PK sampling follow‑
ing a 21‑day herbal medicine washout. Blood sampling was repeated after 14 days of nevirapine and moringa (1.85 g 
leaf powder/day) co‑administration. Nevirapine plasma concentrations were determined by liquid chromatography‑
tandem mass spectrometry. To assess the effect of moringa on nevirapine PK, the change in nevirapine area under the 
plasma concentration–time curve (AUC) was determined. The mean difference in pre‑ and post‑moringa nevirapine, 
maximum concentration (Cmax) and concentration at 12 h (C12h) were also calculated. The PK parameters were com‑
pared by assessing the post/pre geometric mean ratios (GMRs) and associated 90% confidence intervals (CIs).
Results: Pharmacokinetics analyses were performed on the results from 11 participants for whom complete data 
were obtained. The post/pre GMRs and associated 90% CIs for nevirapine were 1.07 (1.00–1.14) for the AUC; 1.06 
(0.98–1.16) for Cmax and 1.03 (0.92–1.16) for C12h.
Conclusion: Co‑administration of Moringa oleifera Lam. leaf powder at the traditional dose did not significantly alter 
the steady‑state PK of nevirapine.
Trial registration number NCT01410058 (ClinicalTrials.gov)
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Background
Concomitant use of herbs with drugs may result in herb-
drug interactions through various pharmacokinetic and 
pharmacodynamic mechanisms [1, 2]. The risk of inter-
action increases with the number of co-administered 
agents. As a result, HIV patients in developing countries 
are at high risk of herb-drug interactions because of the 
widespread self-directed herbal medicine use; and the 
polypharmacy associated with HIV treatment [3].
A growing number of studies are being conducted to 
evaluate the pharmacokinetic effects of herbs on drugs 
when taken together. However, the majority of studies use 
preclinical in  vitro and animal models, which generate 
data that often do not translate to a clinical effect [4, 5]. 
In addition, currently available data are skewed towards 
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Chinese and Western herbs. Given the high prevalence of 
herbal medicine use and the rapid scaling up of treatment 
for HIV infection in developing countries, rigorous clini-
cal studies are urgently required to assess the effects of 
commonly used herbal medicines on antiretroviral drugs. 
This will provide evidence to accurately guide herbal 
medicine use among HIV-infected people who choose to 
take herbs and drugs together.
In developing countries, the leaf powder of Moringa 
oleifera Lam. is commonly used as a medicinal herb, 
rather than food as is the case in Asian populations. It 
is often taken as a supplement by HIV-infected people 
to enhance immunity and manage opportunistic infec-
tions [6, 7]. In-vitro data suggest that moringa inhib-
its cytochrome P450 (CYP) 3A4, 1A2 and 2D6 activity 
which could potentially lead to metabolic interactions 
with antiretroviral drugs metabolized via the same path-
ways [5, 8, 9]. The non-nucleoside reverse transcriptase 
inhibitor nevirapine (200 mg twice daily) is widely used 
as a component of first line antiretroviral therapy in 
many developing countries. It is metabolized mainly by 
CYP3A4 and CYP2B6 and to a lesser extent CYP3A5, 
CYP2C9, and CYP2D6 [10, 11]. Previous studies have 
demonstrated that concomitant administration of flu-
conazole, a potent inhibitor of CYPs, results in mark-
edly increased trough plasma nevirapine concentrations 
when compared to the administration of nevirapine alone 
[12]. Concomitant dosing with the herb St. John’s wort, 
a CYP3A4 and P-glycoprotein inducer, reduced exposure 
to nevirapine [13]. Such interactions with CYP inhibi-
tors or inducers could potentially increase toxicity [11] 
or reduce efficacy, respectively. Prior to this study, it was 
not known whether the in  vitro inhibition potential of 
Moringa oleifera Lam. is of clinical significance when co-
administered with nevirapine. It was hypothesized that 
inhibition of CYP3A4 by M. oleifera leaf powder may 
result in a clinically significant increase in nevirapine 
exposure. This study was conducted to assess the effect of 
14 days Moringa oleifera leaf powder supplementation on 




HIV-infected male and female adults reporting for rou-
tine HIV clinic visits at a referral hospital in Zimbabwe 
were identified through an interviewer-administered 
questionnaire. To be enrolled in the study, participants 
had to be  >18  years old, on an nevirapine based regi-
men for at least 2 weeks and to have supplemented their 
antiretroviral therapy with herbal medicine of their own 
accord in the past. Exclusion criteria included anemia 
(hemoglobin  <10  g/dL), impaired renal function (serum 
creatinine  >300  µmol/L) or abnormal hepatic function 
(serum alanine transaminase  >5 times the upper limit 
of normal) at enrolment, and current treatment with 
rifampicin, isoniazid or imidazoles. All concomitant 
medications were also evaluated on a case by case basis 
and current literature reviewed to exclude any drugs with 
potential to interact with nevirapine. In addition, female 
participants were required to have a negative pregnancy 
test and not to be breastfeeding.
Preparation and analysis of moringa
Fresh Moringa oleifera Lam. leaves positively identified 
by a botanist from the National Botanical Gardens were 
harvested from a rural district in Zimbabwe. A voucher 
specimen was retained and another deposited at the 
National Herbarium and Botanical Gardens of Zimba-
bwe (ref. GPS 13504-C). The leaves were then room dried 
and coarsely ground into powder using a kitchen blender 
according to the method published by the Moringa Asso-
ciation of Ghana (batch MO001 [14]. The dried leaf pow-
der was assessed for microbial and heavy metal content 
and a chemical fingerprint of the methanol extract was 
generated by ultra-performance liquid chromatography 
(UPLC) coupled to a time of flight mass spectrometer 
(TOF MS ES+). The fingerprint was archived at the Uni-
versity of Zimbabwe College of Health Sciences.
Dosage regimen and standardization
In the authors’ experiences and findings from previ-
ous surveys, moringa leaf powder is consumed in a wide 
range of doses [6, 15]. The dose of moringa for the trial 
was planned at approximately two teaspoons (10  mL) 
once a day because it was within the reported range and 
could also be encapsulated into a reasonable number of 
capsules that would not be a barrier to adherence. This 
was equivalent to about 1.85 g of the dry leaf powder. To 
standardize the dose, each 1.85 g dose was weighed out 
and filled into hard gelatin capsules. This was equivalent 
to 4 size ‘000’ capsules. Each participant was supplied 
with enough capsules for the 2-week period.
Study design and treatments
An open label, two phase, one sequence, cross-over, 
pharmacokinetic study was conducted over 35 days. The 
study had a minimum 3-week herbal medication wash 
out period prior to the first dosing to reduce the pos-
sibility of carryover from any type of previously used 
moringa or other herbal medication, so the participants 
would have the same baseline. On the first visit (day one), 
all enrolled participants were instructed not to take any 
herbal supplements, including moringa. They were also 
counseled to continue taking their regular antiretroviral 
drug regimen supplied at the HIV outpatient clinic which 
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included 200  mg nevirapine twice daily. On the second 
visit (day 22), serial whole blood (5 mL) samples and spot 
urine sample were collected for determination of baseline 
plasma nevirapine concentration and urinalysis, respec-
tively. Pre-dose urine and blood samples were collected 
immediately before an observed nevirapine morning 
dose. Additional pharmacokinetic blood samples were 
also collected via cannula at 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 
12  h post nevirapine dose. Participants were given fur-
ther counseling and instructions to continue taking the 
regular antiretroviral drug regimen supplied at the HIV 
outpatient clinic together with moringa supplied by the 
study staff. On the third visit (day 35), a second set of 
serial whole blood (5 mL) samples and a spot urine sam-
ple were collected for determination of post-moringa 
plasma nevirapine concentration and urinalysis. Pre-dose 
urine and blood samples were again collected immedi-
ately before an observed nevirapine morning dose, and 
additional pharmacokinetic blood samples collected via 
cannula at 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 h post nevirap-
ine dose. The observed dose of nevirapine was adminis-
tered in the fed state on both visits. On blood sampling 
days, a standard diet was provided and participants were 
required to remain on-site over the course of both 12 h 
intensive sampling periods.
Documentation of adherence to medication and sup-
plementation restrictions between visits was achieved 
through the use of a food/herb/medication diary. Expo-
sure to moringa was based on self-reported adherence 
and assessed through personal interviews, pill counts and 
evaluation of the food/herb/medication diary.
Assessment of adverse events
All participants were monitored for adverse events 
throughout the study. The study medical officer docu-
mented any adverse events observed from clinical exami-
nations or self-reported by the participants at each visit.
Sample preparation
Blood samples were collected into 10-mL tubes contain-
ing ethylenediaminetetraacetic acid (EDTA) for determi-
nation of nevirapine concentration. All blood specimens 
were centrifuged at 2800×g for 5 min at 4 °C. The plasma 
was harvested and stored at −80 °C until time of analysis.
Determination of nevirapine
Nevirapine concentrations were determined by LC–MS/
MS in the laboratory of the Division of Clinical Pharma-
cology, University of Cape Town. The assay method has 
been reviewed by the AIDS Clinical Trials Group Quality 
Assurance and Quality Control program (ACTG CPQA). 
It was validated according to the United States Food and 
Drug Administration and European Medicines Agency 
guidelines using externally prepared proficiency testing 
samples supplied by the ACTG CPQA.
Plasma samples were extracted from 100  µL human 
plasma by protein precipitation using acetonitrile (Hon-
eywell, Burdick & Jackson®). The extraction procedure 
was followed by liquid chromatography with MS/MS 
detection. Chromatographic separation was achieved on 
a Luna 5 μm PFP (2), 100 A, 50 mm × 2 mm analytical 
column column (Phenomenex, Torrance, CA, U.S.). An 
AB Sciex API 4000 mass spectrometer (SCIEX, Framing-
ham, MA, U.S.) was operated at unit resolution in the 
multiple reaction monitoring (MRM) mode, monitoring 
the m/z 266.9 (MH+) → 198.2 transition for nevirapine, 
and the m/z 270.1 → 229.1 transition for the deuterated 
nevirapine internal standard. The calibration curve was 
fitted by quadratic regression (weighted by 1/concentra-
tion2) over the range 0.0195–20.0 µg/mL. The combined 
accuracy and precision statistics of the low, medium and 
high quality control samples during sample analysis were 
between 89.8 and 93.4%, and 4.2 and 9.1%, respectively.
Statistical and pharmacokinetic analysis
In designing the study, a difference in pre- and post-
moringa nevirapine area under the plasma concentra-
tion–time curve from 0 to 12 h (AUC0–12h) of at least 20% 
was considered to be clinically relevant for the purpose of 
establishing sample size. An intra-individual coefficient 
of variation of 25% was assumed for nevirapine AUC 
based on previously published data [16]. With α = 0.05, it 
was determined that a total of 12 participants would pro-
vide 80% power in the case of an equivalence range 0.8–
1.25 [17]. After making adjustments for loss to follow-up 
(10%) and the cross-over design, a sample size of 13 was 
targeted.
Statistical analyses were performed using StataMP® 
version 13 (StataCorp, College Station, TX). Demo-
graphic characteristics were summarized as means and 
standard deviations or frequencies. Nevirapine pharma-
cokinetic parameters [i.e. AUC0–12h, peak concentration 
(Cmax,ss) and concentration at 12 h post dose (C12h)] were 
calculated for each individual using a non-compartmen-
tal approach by means of the Phoenix WinNonlin soft-
ware application (Version 6.0; Certara, Princeton, NJ). 
AUC was calculated using the linear trapezoidal method. 
The individual differences in the pharmacokinetic param-
eters were calculated on log transformed data. The con-
fidence interval approach was used to assess the effect 
of moringa on the pharmacokinetics of nevirapine. To 
evaluate if pharmacokinetic changes could have clinical 
relevance, it is recommended to treat pharmacokinetic 
interactions as equivalence problems [18]. Absence of a 
moringa effect was assumed if the 90% confidence inter-
val (CI) of the geometric mean ratio (GMR) of AUC0–12h, 
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Cmax,ss and C12h with and without moringa were con-
tained within the limits 80–125%. The significance of the 
GMR results were assessed by paired Student t test.
Post-moringa/pre-moringa geometric mean ratios 
(GMRs) and their confidence intervals were calculated as 
follows: GM[x] = 10^mean[log[x]]; GMR[y/x] = GM[y]/
GM[x]. The 90% confidence interval (CI) of GMR[t2/
t1] was calculated from the difference in the logs (DL) 
of the t2 and t1 values: DL[t2,t1]  =  log[t2]–log[t1], 
where t2 and t1 are corresponding values for the same 
subject post-moringa and pre-moringa, for 11 sub-
jects. If m  =  mean[DL[t2,t1]], sd  =  standard devia-
tion [DL[t2,t1]], and (a,b) =  CI[m,sd,n], then the CI of 
GMR[t2/t1] = (10^a,10^b) and GMR[t2/t1] = 10^m. The 
confidence intervals of the DL values were also verified 
with that obtained by the statistical package.
Results
Participant enrolment
Thirty-three HIV-infected adult patients were screened. 
Thirteen participants met the eligibility criteria and were 
enrolled after giving oral and written informed consent. 
All participants completed the study. Based on pill counts 
and a review of entries in the food/herb/medication 
diaries, all participants were fully compliant with medi-
cation and supplementation restrictions. The baseline 
demographic characteristics are summarized in Table 1.
Adverse events
The combination of moringa with nevirapine was well 
tolerated. Participants were in good health upon physi-
cal examination at the post moringa visit. There were no 
serious adverse events and all participants completed the 
study. A total of two adverse events were reported by the 
participants; one complained of transient mild pain at 
the site of cannula insertion and the other, a headache. 
During the observation period, only grade 1 Common 
Terminology Criteria for Adverse Events (CTCAE) tox-
icities were observed in the clinical assessments. The 
incidence rate was 5% (n = 202 readings), and there were 
no significant differences in the number observed pre-
moringa compared to post-moringa. The medical officer 
and consultant physician monitoring adverse events in 
the study decided these were not related to the moringa.
Pharmacokinetics
Pharmacokinetic analyses were performed on the results 
from 11 participants who had complete data. Of the two 
participants that were excluded, one had difficulties with 
venous access at points during visit 2. The other took the day 
35 nevirapine dose at home instead of at the clinic such that 
only samples for the latter time points could be collected.
Figure  1 shows the mean plasma concentration–time 
profiles for nevirapine with and without Moringa oleifera 
leaf powder supplementation (Figs. 2, 3, 4).
Table 1 Baseline characteristics of  the study population, 
n = 13
a Other drugs included pyridoxine, hydrochlorothiazide, indomethacin, 
diclofenac and enalapril
Characteristic Value
Age (years), mean ± SD 44 ± 8
Sex, female, n (%) 8 (73)
Weight (kg), mean ± SD 63.5 ± 7.5
Drug frequency n (%)
 Nevirapine 13 (100)
 Tenofovir/lamivudine 10 (77)
 Stavudine/lamivudine 2 (15)
 Zidovudine/lamivudine 1 (8)
 Cotrimoxazole 9 (69)






























Fig. 1 Mean nevirapine plasma concentration–time profile with and 






















Pre-moringa                            Post-moringa
Fig. 2 Individual AUC 0–12 of nevirapine with and without moringa. 
All patients maintained therapeutic plasma concentrations (>3.0 µg/
mL) 12 h post‑dose [19]
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The plasma pharmacokinetics parameters and compar-
isons for nevirapine are presented in Table 2.
Discussion
Based on previous in  vitro studies that have noted sig-
nificant inhibitory effects of moringa on the nevirapine-
metabolizing CYP3A4 and CYP2D6 isoforms, the effect 
of Moringa oleifera leaf supplementation on nevirapine 
pharmacokinetics was investigated. While the nevirap-
ine pharmacokinetic profiles from HIV-infected adults 
at the dosage of moringa used show an inhibitory trend, 
consistent with that observed in vitro [5, 8, 9], the change 
in steady-state nevirapine pharmacokinetic parameters 
is neither clinically nor statistically significant. The 90% 
confidence intervals for the nevirapine geometric mean 
ratios for AUC0–12h, Cmax,ss and C12h following concomi-
tant administration of moringa over 14 days were within 
the 80–125% limit, indicating lack of a clinically signifi-
cant interaction.
The findings are supported by observations from previ-
ous studies that demonstrated that the inhibitory effects 
of moringa on CYP3A4 and CYP2D6 are significantly less 
as compared to their positive control inhibitors ketocon-
azole and quinidine [20]. Data from other studies show 
that nevirapine induces its metabolism by both CYP3A4 
and CYP2B6, which may compensate to some degree 
for CYP3A4 inhibition [21] Any inhibition of CYP3A4 
may also have been compensated for by the alterna-
tive metabolic pathways (CYP2B6, CYP3A5, CYP2C9, 
and CYP2D6) reducing the resulting pharmacokinetic 
changes [22, 23]. This may not be the case for other drugs 
such as saquinavir, ritonavir, indinavir, darunavir and 
atazanavir whose main or sole route of elimination is via 
CYP3A4.
In general, moringa has a good safety profile consist-
ent with its long history of use as food and medicine 
[24]. The combination of moringa and nevirapine in this 
study was also well tolerated since moringa did not alter 
the safety profile of nevirapine when co-administered. A 
minimum concentration of 3.0  µg/mL is recommended 
as a therapeutic cut-off for nevirapine trough concen-
trations [19]. All patients maintained nevirapine 12-h 
concentrations above 3.0  µg/mL with moringa sup-
plementation. Because the study did not assess clinical 
outcomes, this observation cannot be discussed in terms 
viral load.
The toxicity of nevirapine as a function of concentra-
tion is not well established. Some studies could not find 
evidence of a concentration—toxicity relationship while 
others report an association between hepatotoxicity and 
higher nevirapine concentrations [25–28]. In this study, 
no nevirapine related adverse effects were reported 
despite the C12h and Cmax,ss values observed being mostly 
higher than the 6 µg/mL value previously associated with 
increased toxicity. The findings are consistent with Thai 
and Ugandan data that did not detect increased toxicity, 
despite increases in nevirapine Ctrough.
One limitation of the study is that for operational econ-
omy, a single sequence of moringa administration was 






















Pre-moringa                          Post-moringa
Fig. 3 Individual Cmax,ss of nevirapine with and without moringa. 
All patients maintained therapeutic plasma concentrations (>3.0 µg/
















Pre-moringa                         Post-moringa
Fig. 4 Individual C12 of nevirapine with and without moringa. All 
patients maintained therapeutic plasma concentrations (>3.0 µg/mL) 
12 h post‑dose [19]
Table 2 Comparison of  nevirapine pharmacokinetic 
parameters pre- and post- moringa
a Post‑moringa/pre‑moringa geometric mean ratios (GMRs) and 
their confidence intervals were calculated as follows: GM[x] = 10^{m} 
ean[log[x]];GMR[y/x] = GM[y]/GM[x]
GMR geometric mean ratio, CI confidence interval, AUC0–12h area under the time‑
concentration curve from 0 to 12 h after dosing, Cmax,ss maximum concentration, 
C12h concentration at the end of the dosing interval
Parameter GM (CV %)a GMR (90% CI)a
Pre-moringa Post-moringa Post/Pre P
AUC0–12h (h*µg/
mL)
94.17 (25.24) 100.44 (27.65) 1.07 (1.00–1.14) 0.131
C12h (µg/mL) 7.30 (25.85) 7.55 (28.56) 1.03 (0.92–1.16) 0.702
Cmax,ss (µg/mL) 9.92 (26.93) 10.57 (29.62) 1.06 (0.98–1.16) 0.261
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Conclusions
We conclude that co-administration of moringa leaf pow-
der at traditionally used doses has no clinically significant 
effect on the steady-state pharmacokinetics of nevirapine.
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